Pfizer posts flat Q3 revenue, raises FY‑2026 outlook and names new CFO
+8 new sources since this summary was written
Pfizer reported third‑quarter 2026 revenue of $16.6 billion, essentially unchanged year‑over‑year, while adjusted earnings per share were $0.87. The company lifted its full‑year 2026 revenue target to $62‑$64 billion and adjusted EPS guidance to $2.95‑$3.05, and appointed Cecile Guegan as permanent chief financial officer effective November 1, 2026.
Why it matters
The raised guidance signals management’s confidence in non‑COVID product growth and should support the stock’s valuation, as noted by the company’s own statement in the earnings release (). The CFO appointment may affect future capital‑allocation decisions, according to the company announcement ().
Key facts
- 1Third‑quarter 2026 revenue was $16.6 billion, flat year‑over‑year. stocktitan.net
- 2Adjusted diluted EPS for the quarter was $0.87. stocktitan.net
- 3GAAP diluted EPS fell 9% year‑over‑year to $0.56. stocktitan.net
- 4Excluding Comirnaty and Paxlovid, revenue grew 7% operationally. stocktitan.net
- 5Revenue from launched and acquired products grew 32% operationally. stocktitan.net
- 6Full‑year 2026 revenue guidance was raised to $62‑$64 billion. stocktitan.net
Summary written by AlphAI AI Desk from 20 of 25 sources. Not investment advice. Figures are as stated by the linked sources.